Palforzia® is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. Palforzia® may be continued in patients 18 years of age and older. Palforzia® should be used in conjunction with a peanut-avoidant diet.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||01/04/2022|
|Rapid review completed||04/05/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of Palforzia® compared with the current standard of care.|